biotech / news / / Seeking Alpha
Novo Nordisk A/S reported Q1 '26 headline growth, but adjusted EPS and revenue declined due to a one-off US 340B benefit exclusion.
Novo Nordisk's Q1 '26 adjusted EPS and revenue declined due to a one-off US 340B benefit exclusion.
KEY POINTS
- Despite robust GLP-1 franchise volume growth, the company faces enduring U.S. pricing pressure and margin compression.
- Novo Nordisk trades at a 25% discount to sector median P/E and over 50% below historical EV multiples.
- FY26 guidance is cautious, reflecting current margin pressures despite dominance in obesity and diabetes therapeutics.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →